1.800USD-2.70%Mkt Cap: 336.29M USDP/E: —Last update: 2026-05-26
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. Th…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap336.29M USD
Enterprise Value225.64M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-236.93M USD
Revenue/Share—
Last Price1.800 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees96
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.08
PEG—
EV/EBITDA-0.96
EV/Revenue—
P/S—
P/B3.10
EPS (TTM)-1.33
EPS (Forward)-0.89
52W Range
0.658038% of range3.650
52W High3.650 USD
52W Low0.6580 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-228.10%
ROA-124.02%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-206.44M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-34.41%
Net Debt-127.52M USD
Net Debt/EBITDA0.54
Balance Sheet
Debt/Equity0.53
Current Ratio5.87
Quick Ratio5.63
Book Value/Sh0.5960 USD
Cash/Share1.003 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.8 (Buy)
Target (Mean)8.908 USD
Target Range3.000 USD – 18.00 USD
# Analysts8
Ownership
Shares Out.185.28M
Float104.83M
Insiders23.93%
Institutions55.90%
Short Interest
Short Ratio3.8d
Short % Float4.27%
Short % Out.2.45%
Shares Short4.47M
Short (prev mo.)4.96M
Technical
SMA 502.213 (-18.7%)
SMA 2002.188 (-17.7%)
Beta3.05
S&P 52W Chg28.31%
Avg Vol (30d)1.45M
Avg Vol (10d)1.29M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—